KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) EBT (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of EBT data on record, last reported at $25.7 million in Q4 2025.

  • For Q4 2025, EBT rose 259.89% year-over-year to $25.7 million; the TTM value through Dec 2025 reached $137.7 million, up 71.44%, while the annual FY2025 figure was $138.9 million, 46.18% down from the prior year.
  • EBT reached $25.7 million in Q4 2025 per ACAD's latest filing, down from $44.6 million in the prior quarter.
  • Across five years, EBT topped out at $44.6 million in Q3 2025 and bottomed at -$112.6 million in Q1 2022.
  • Average EBT over 5 years is -$10.7 million, with a median of -$15.4 million recorded in 2021.
  • The widest YoY moves for EBT: up 486.19% in 2024, down 140.52% in 2024.
  • A 5-year view of EBT shows it stood at -$42.9 million in 2021, then grew by 4.8% to -$40.8 million in 2022, then skyrocketed by 197.21% to $39.7 million in 2023, then tumbled by 140.52% to -$16.1 million in 2024, then skyrocketed by 259.89% to $25.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were $25.7 million in Q4 2025, $44.6 million in Q3 2025, and $40.2 million in Q2 2025.